Differential expression of gluconeogenic enzymes in early- and late-stage diabetes: the effect of Citrullus colocynthis (L.) Schrad. Seed extract on hyperglycemia and hyperlipidemia in Wistar-Albino rats model

• Published in: Clinical phytoscience 2021-11, Vol.7 (1), p.1-22, Article 88
• Main Authors: Afshari, Arezoo, Salimi, Fouzieh, Nowrouzi, Azin, Khalili, Masoumeh Babaie, Bakhtiyari, Salar, Hassanzadeh, Gholamreza, Shabani, Maryam, Ahadi, Ali, Farhadiannezhad, Masoumeh
• Format: Article
• Language: English
• Subjects: Acetyl-CoA carboxylase; Alanine; Alkaline phosphatase; Animal models; Carbonyl compounds; Carbonyls; Carnitine; Carnitine palmitoyltransferase; Citrullus colocynthis; Citrullus colocynthis (L.) Schrad; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetes mellitus (non-insulin dependent); Early- and late-stage diabetes mellitus; Fatty acids; Fatty-acid synthase; Ferulic acid; Gastroenterology; Gene expression; Gluconeogenesis; Glucose; Glucose tolerance; Glucose-6-phosphatase; Gynecology; Herbal medicine; High-performance liquid chromatography; Hyperglycemia; Hyperlipidemia; Insulin; Liquid chromatography; Liver; Medicinal plants; Medicine; Medicine & Public Health; Morphology; Original Contribution; Oxidative stress; Palmitoyltransferase; Pediatrics; Phosphatase; Pneumology/Respiratory System; Polymerase chain reaction; Proteins; Rutin; Sterol regulatory element-binding protein; Triglycerides; Urea; Wistar-albino rats
• ISSN: 2199-1197; 2199-1197
• DOI: 10.1186/s40816-021-00324-x

Background The medicinal plant Citrullus colocynthis (L.) Schrad. ( C. colocynthis ) may benefit patients at different phases of diabetes by attuning to contrasting situations. Our primary objective was to find the mechanism(s) behind the antidiabetic/anti-hyperlipidemic effects of C . c olocynthis seed a queous e xtract (CCAE) in two different stages of type 2 diabetes (T2D) in rats. Methods Fasting blood sugar (FBS) levels, body weights, and the degree of impaired glucose tolerance (IGT) were measured in healthy nondiabetic control rats (Con), as well as rats with e arly and l ate stages of T2D , denoted as ET2D and LT2D, respectively. CCAE was intraperitoneally (IP) injected for 28 days. In the end, the hepatic mRNA expression levels of the following genes were determined by RT-PCR: glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase (PEPCK), insulin-dependent sterol regulatory element-binding protein-1c (SREBP-1c), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), peroxisome proliferator-activated receptor alpha (PPARα), and carnitine palmitoyltransferase I (CPT1). The liver was examined by hematoxylin and eosin (H&E) and Oil-Red O staining. CCAE was partially analyzed by HPLC-DAD. Results ET2D and LT2D were characterized by differentially elevated FBS, deteriorated bodyweight, and significant IGT compared to Con. Hepatosteatoses of varying morphologies and higher hepatic expression of G6Pase than PRPCK in ET2D versus the opposite in LT2D further confirmed the divergent nature of metabolic aberrations. At the end of 28 days, the high levels of FBS, alkaline phosphatase (ALP), triglyceride (TG), urea, hepatic protein carbonyl content (PCC), and alanine and aspartate aminotransferases (AST and ALT, respectively) persisted in untreated LT2D. CCAE ameliorated oxidative stress and upregulated PPARα expression in diabetic groups and Con; it downregulated CPT1 expression in the LT2D group. CCAE’s ability to lower FBS and serum and hepatic TG in both ET2D and LT2D indicated its ability to act via different mechanisms. Ferulic acid (Fer A) and rutin hydrate (RH) were detected in CCAE. Conclusion CCAE lowered the FBS in ET2D via inhibiting the hepatic G6Pase expression (glycogenolysis). In LT2D, CCAE abated sugar levels by diverting PEPCK activity, preferably towards glyceroneogenesis than gluconeogenesis. The preserved triglyceride/fatty acid (TG/FA) cycle, the upregulated PPARα, and the downregulated CPT1 gene expressions reduced serum and